Toronto, Ontario and Chicago, Illinois – June 24, 2025 – Nexera Pharmaceuticals is excited to announce its intention to go public with a listing on the New York Stock Exchange (NYSE) in August 2025. This strategic move marks a pivotal milestone in Nexera’s growth journey, opening new opportunities to accelerate innovation, expand its product portfolio, and deliver greater value to patients and partners across North America and beyond.
The NYSE is renowned as the premier venue for global capital raising, supporting companies in scaling their businesses, creating jobs, and elevating their brands on the world stage. By joining the NYSE, Nexera aims to leverage this dynamic platform to fuel its next phase of expansion and to further its mission of transforming healthcare through specialty and rare disease medicines.
CEO statement:
“Taking Nexera public on the New York Stock Exchange is a transformative step for our company and the communities we serve. This listing will provide us with access to greater capital resources, enabling us to accelerate research and development, broaden our reach, and invest in the next generation of life-changing therapies. We are committed to maintaining our focus on quality, innovation, and patient outcomes as we embark on this exciting new chapter. Our team is energized by the opportunities ahead, and we look forward to welcoming new investors to join us on our mission to advance global healthcare.”
– Ashok Kumar
Benefit of the NYSE listing
- Increased Access to Capital: The IPO will provide Nexera with significant resources to invest in R&D, expand its specialty and generic medicine offerings, and pursue strategic partnerships.
- Enhanced Visibility and Credibility: Listing on the NYSE elevates Nexera’s profile among global investors, partners, and the broader healthcare community.
- Talent Attraction and Retention: As a public company, Nexera will be better positioned to attract top talent and retain key employees through equity participation.
- Accelerated Innovation: The capital raised will support Nexera’s ongoing commitment to developing cutting-edge therapies for complex and underserved conditions.
Nexera Pharmaceuticals is dedicated to keeping stakeholders informed as the IPO process advances and will provide further updates as the listing date approaches.
About Nexera Pharmaceuticals
Nexera Pharmaceuticals is a leader in specialty and rare disease medicines, committed to delivering innovative healthcare solutions that improve lives.
Forward-Looking Statements: This press release contains forward-looking statements regarding the planned IPO and future business plans. Actual results may differ due to various factors. Nexera undertakes no obligation to update these statements except as required by law.